~~IMMUNOCONJUGATES COMPRISING AN ANTI-CEA ANTIBODY LINKED BY CONJUGATION TO ONE OR|MORE 8-HET-2-AMINOBENZAZEPINE DERIVATIVES USEFUL IN TREATING CANCER~~ ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF

CROSS REFERENCE TO RELATED APPLICATIONS

This non-provisional application claims the benefit of priority to U.S. Provisional Application No. 63/124,328, filed 11 December 2020, which is incorporated by reference in its entirety.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on December 3, 2021, is named 17019_010WO1_SL.txt and is 55,248 bytes in size.

FIELD OF THE INVENTION

The invention relates generally to an immunoconjugate comprising an anti-Carcinoembryonic Antigen (CEA) antibody conjugated to one or more 8-Het-2-aminobenzazepine molecules.

BACKGROUND OF THE INVENTION

New compositions and methods for the delivery of antibodies and immune adjuvants are needed in order to reach inaccessible tumors and/or to expand treatment options for cancer patients and other subjects. The invention provides such compositions and methods.

SUMMARY OF THE INVENTION

The invention is generally directed to immunoconjugates comprising an anti-CEA antibody linked by conjugation to one or more 8-Het-2-aminobenzazepine derivatives. The invention is further directed to 8-Het-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of immunoconjugates wherein an antibody may be covalently bound by a linker L to a 8-Het-2-aminobenzazepine (HxBz) moiety having the formula:

